Skip to Content
You are currently on the new version of our website. Access the old version .
VaccinesVaccines
  • Review
  • Open Access

30 August 2025

24 Pages

Immune Response to MVA-BN Vaccination for Mpox: Current Evidence and Future Directions

,
,
,
,
,
,
and
1
Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, D04 V1W8 Dublin, Ireland
2
Department of Infectious Diseases, St Vincent’s University Hospital, Elm Park, D04 TC63 Dublin, Ireland
3
Center for Tropical Diseases and Global Health, Faculty of Medicine, Catholic University of Bukavu, Bukavu 73, Congo
4
Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 7505, South Africa

Abstract

The 2022 global mpox outbreak, caused by clade IIb of the monkeypox virus (MPXV), prompted emergency use authorisation of the Modified Vaccinia Ankara–Bavarian Nordic (MVA-BN) vaccine, previously approved for smallpox prevention. Understanding immune responses to the MVA-BN vaccine is critical to inform both current and future mpox vaccine policy, particularly amid reports of breakthrough infections in vaccinated persons, uncertainty about the durability of vaccine-induced protection, and the emergence of further outbreaks of mpox from different viral clades, including the clade I-driven public health emergency of international concern. MVA-BN elicits binding and neutralising antibody, memory B cells, and T cell responses. Immune responses vary by host factors, prior orthopoxvirus exposure, and dosing regimens. While seroconversion is generally robust, circulating antibody titres often wane rapidly, particularly in vaccinia-naïve and/or immunocompromised individuals, including people with HIV. Vaccine-induced neutralising antibody responses to MPXV are frequently lower than to vaccinia virus, and their role in protection remains ill-defined. In contrast, T cell responses appear more sustained and may support long-term immunity in the absence of persistent antibody titres. This narrative review synthesises current evidence on the immunogenicity and durability of MVA-BN vaccination, highlights challenges in assay interpretation, and outlines key research priorities, including the need to explore correlates of protection, booster strategies, and next-generation vaccine design.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.